Coherus Oncology (NASDAQ:CHRS – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Insider and Institutional Ownership
72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Coherus Oncology and CRISPR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coherus Oncology | -253.43% | -274.46% | -69.87% |
| CRISPR Therapeutics | -1,812.07% | -25.59% | -17.89% |
Valuation and Earnings
This table compares Coherus Oncology and CRISPR Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coherus Oncology | $42.17 million | 1.93 | $168.02 million | ($0.97) | -0.54 |
| CRISPR Therapeutics | $3.51 million | 1,167.32 | -$581.60 million | ($4.74) | -8.91 |
Coherus Oncology has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Coherus Oncology has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Coherus Oncology and CRISPR Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coherus Oncology | 1 | 0 | 3 | 0 | 2.50 |
| CRISPR Therapeutics | 1 | 6 | 8 | 2 | 2.65 |
Coherus Oncology currently has a consensus target price of $11.00, suggesting a potential upside of 1,993.24%. CRISPR Therapeutics has a consensus target price of $72.93, suggesting a potential upside of 72.65%. Given Coherus Oncology’s higher possible upside, research analysts plainly believe Coherus Oncology is more favorable than CRISPR Therapeutics.
Summary
Coherus Oncology beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.
About Coherus Oncology
Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.
About CRISPR Therapeutics
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
